Results 251 to 260 of about 74,157 (302)

Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study. [PDF]

Cureus
Aldebei A, Hammouri YS, Abdallat SA, Hjazeen A, Muhanna AM, Arnous H, Alshwayyat R, Alkotob M.   +7 more
europepmc   +1 more source

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease. [PDF]

J Crohns Colitis
Su J, Lartey DA, Zanella G, Hawinkels LJAC, Matteoli G, Löwenberg M, Barnhoorn MC.   +6 more
europepmc   +1 more source

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris   +10 more
wiley   +1 more source

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team. [PDF]

Intest Res
Hong SM, Kim DH, Bae JH, Shin SY, Song EM, Kim JE, Yang YJ, Yoon J, Kang SB, Kim ES, Kim SE, Kim SJ, Lee J, Na SY, Park SJ, Park SH, Choi M, Kim MH, Moon W, Jung SA.   +19 more
europepmc   +1 more source

The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias.

Int J Trichology
Balfour AN, Osborne S, Mesinkovska NA.
europepmc   +1 more source

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

The Cochrane Library, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J Martí-Carvajal, Ivan Sola
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources

Janus kinase inhibitors for alopecia areata

Journal of the American Academy of Dermatology, 2023
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire   +2 more sources

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Efficacy of Janus kinase inhibitors in rheumatoid arthritis

Inflammation Research, 2023
Janus kinase inhibitors (JAKis) is a new therapeutic class in autoimmune and inflammatory diseases. Four molecules are approved in rheumatoid arthritis (RA) in Europe. Recently, questions have raised about adverse events. In this context, a synthesis of the efficacy data of JAKis in RA is of use.We performed a literature review based on published ...
Camille, Langbour, Jessica, Rene, Philippe, Goupille, Guillermo, Carvajal Alegria   +3 more
openaire   +2 more sources